AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

, a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its AI-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year agreement. 

Under an agreement announced on January 28, 2026, Noul will exclusively supply 100 miLab CER units over four years through a partnership with a major distributor in Mexico. The deal follows a 1.1-billion-won agreement last year to supply miLab CER systems in Panama and reflects the company’s strategy to further expand its presence across Latin America. Noul also reported obtaining MDSAP certification, which meets integrated quality standards across major markets in North and Latin America, and said it plans to accelerate global business expansion in the region.

"Mexico is a strategic hub for expanding into the Latin American market, and miLab CER will play a key role in driving Noul’s sales growth and profitability throughout Latin America in the future.” said Noul CEO Lim Chan-yang. “This year, Noul will focus on maximizing sales and improving profitability by accelerating the expansion of supply to major overseas markets such as Latin America and Europe, centered on high-value-added new products including not only our AI-based cervical cancer solution but also blood analysis solutions. Through this, we will secure continuous growth momentum for our global business.

Noul's miLab CER is a digital cervical cell analysis solution that integrates automated staining, imaging, and AI-based evaluation of smeared cervical cell slides into a single device, replacing the traditionally complex workflow and supporting infrastructure. Its AI algorithm analyzes approximately 25,000 cells per sample, classifies findings according to the Bethesda system, and identifies signs of precancerous and cancerous lesions. Medical professionals can review and, if needed, reclassify results either on-site or remotely via a dedicated viewer, enabling rapid and accurate decisions on whether immediate treatment or referral to a higher-level facility is required.

The introduction of miLab CER enables medical institutions that already collect cervical cell samples to perform cervical cancer screening with only minimal additional workflow steps. Because the system automates sample staining, digital imaging, and AI-based analysis, institutions need only smear and fix the collected cervical cells on a slide. As a result, screening results can be shared more rapidly with patients, while institutions can also expand revenue opportunities by offering additional diagnostic tests that were previously unavailable in-house.

Related Links
Noul